Liver transplantation for hepatitis B virus-related liver disease: indications, prevention of recurrence and results. (Q35621731)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14708701%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

review article

1 reference

title

Liver transplantation for hepatitis B virus-related liver disease: indications, prevention of recurrence and results (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14708701%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

main subject

liver transplantation

1 reference

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14708701%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

1

Bruno Roche

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14708701%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

publication date

1 January 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14708701%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

published in

Journal of Hepatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14708701%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

volume

39 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14708701%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

page(s)

S181-9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14708701%20AND%20SRC:MED&resulttype=core&format=json

Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications

17 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Liver transplantation in European patients with the hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplantation model.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Hepatitis B virus mutations in the pre-S genome before and after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Evidence for selection of hepatitis B mutants after liver transplantation through peripheral blood mononuclear cell infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Corticosteroids stimulate hepatitis B virus DNA, mRNA and protein production in a stable expression system

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Survival after liver transplantation for chronic hepatitis B using reduced immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Familial HBsAg-positive hepatoma: treatment with orthotopic liver transplantation and specific immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Liver transplantation and HBsAg-positive postnecrotic cirrhosis: adequate immunoprophylaxis and delta virus co-infection as the significant determinants of long-term prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Impact of immunoprophylaxis and patient selection on outcome of transplantation for HBsAg-positive liver recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Long-term follow-up of hepatitis B virus-infected recipients after orthotopic liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Mercury poisoning associated with high-dose hepatitis-B immune globulin administration after liver transplantation for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

'EUROHEP' consensus report on the management of liver transplantation for hepatitis B virus infection. European Concerted Action on Viral Hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Lamivudine treatment in patients with decompensated hepatitis B cirrhosis: for whom and when?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Favorable outcome of orthotopic liver transplantation in a patient with subacute liver failure due to the emergence of a hepatitis B YMDD escape mutant virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Lamivudine for hepatitis B in liver transplantation: a single-center experience

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Liver transplantation for patients with hepatitis B: prevention of hepatitis B recurrence by intravenous antihepatitis B immunoglobulin and lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose [...]

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

New era of liver transplantation for hepatitis B: a 17-year single-center experience

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Hepatitis B vaccination after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Successful hepatitis B vaccination in patients who underwent transplantation for hepatitis B virus-related cirrhosis: preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Liver transplantation and hepatitis B virus infection: the situation seems to be under control, but the virus is still there

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Patterns of hepatitis delta virus reinfection and disease in liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Delta-infection and suppression of hepatitis B virus replication in chronic HBsAg carriers.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Liver transplantation in hepatitis delta virus disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900335-0

7 January 2021

10.1016/S0168-8278(03)00335-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14708701%20AND%20SRC:MED&resulttype=core&format=json

17 November 2019

1 reference